Welcome
Support Centre
21 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)
ISRCTN ISRCTN79170611
ClinicalTrials.gov identifier
Public title A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)
Scientific title
Acronym N/A
Serial number at source LA01.01.0005
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Huntington's disease
Participants - inclusion criteria 1. Written informed consent
2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
3. Diagnosis of HD in stage I
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2003
Anticipated end date 01/01/2004
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions Two groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis.

Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 month open label phase receiving 2 g/day Ethyl EPA.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Laxdale Ltd (UK)
Trial website
Publications
Contact name Dr  Harald  Murck
  Address Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email hmurck@laxdale.co.uk
Sponsor Laxdale Ltd (UK)
  Address Kings Park House
Laurelhill Business Park
Polmaise Road
  City/town Stirling
  Zip/Postcode FK7 9JQ
  Country United Kingdom
  Tel +44 (0)1786 476001
  Fax +44 (0)1786 473137
  Email admin@Laxdale.co.uk
  Sponsor website: http://www.laxdale.co.uk
Date applied 03/02/2003
Last edited 19/05/2008
Date ISRCTN assigned 03/02/2003
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central